Jade Biosciences, Inc.
JBIOHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Jade Biosciences, Inc. (JBIO) is listed under Biotechnology. With a market capitalization of $1.27B, it sits in small-cap territory. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
Market Cap
$1.27B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.47
EPS (TTM)
$-1.07
EPS (Fwd)
$-2.66
ROE
—
ROA
—
Cash
$461.2M
Total Debt
$1.4M
Free CF
—
52W Change
161.2%
Annual Financials
Cash vs Debt
Where JBIO stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, JBIO finished 15.19% above its 150-day moving average ($18.96) and 24.23% above its 200-day moving average ($17.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JBIO overbought or oversold?
At the August 26, 2026 close, JBIO's RSI(14) was 50.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $461.2M in cash and $1.4M in debt, JBIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing JBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.